Suven Life Sciences has informed that it enclosed News Release of the company titled 'Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonist for treatment of Agitation and aggression in Alzheimer's type dementias'. In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended and in terms of the Code of Conduct of the Company for prevention of Insider Trading, the Trading Window for dealing in the securities of the Company shall remain closed for the Directors, Promoters, other Designated Persons, and immediate relatives of Designated Persons covered under the said code read with the SEBI Regulations, from 17th August 2021 to 18th August 2021. Trading window will be opened from 19th August, 2021.
The above information is a part of company’s filings submitted to BSE.
